# STANDARD BIOTOOLS INC. (LAB) — divestiture/carve_out [pending]
Source: SEC API (secapi.ai) · situation sit_4cfaafb238fe3b1379e2 · retrieved 2026-08-12T21:26:01.976Z

## Overview
Standard BioTools Inc. develops, manufactures, markets and sells mass cytometry-based products and technologies, including the CyTOF platform, Hyperion spatial biology platform, Maxpar reagents, and the Theia next-generation XTi platform.

Standard BioTools Inc. agreed to sell its mass cytometry business to Multiplex Bio Inc. pursuant to a Share and Asset Purchase Agreement dated July 28, 2026. The transaction includes the sale of equity interests in the Transferred Companies and substantially all assets related to the mass cytometry business, including the CyTOF platform, Hyperion spatial biology platform, Maxpar reagents, and the Theia next-generation XTi platform. The purchase price consists of $5,000,000 in cash (payable via a promissory note), adjusted for closing date cash, indebtedness, working capital, and transaction expenses, plus up to $5,000,000 in additional consideration if Buyer consummates a Qualifying Exit within ten years of closing.

## Terms
- Counterparty: Multiplex Bio Inc. · Deal value: $5.0M · Consideration: mixed

## Key dates
- Announced 2026-07-29

## Timeline
- 2026-07-29 · 8-K/A (0001140361-26-029964): 8-K/A - STANDARD BIOTOOLS INC. — *Standard BioTools Inc. develops, manufactures, markets and sells mass cytometry-based products and technologies, including the CyTOF platform, Hyperion spatial biology platform, Maxpar reagents, and the Theia next-generation XTi platform.* Standard BioTools Inc. agreed to sell its mass cytometry business to Multiplex Bio Inc. pursuant to a Share and Asset Purchase Agreement dated July 28, 2026. The transaction includes the sale of equity interests in the Transferred Companies and substantially all assets related to the mass cytometry business, including the CyTOF platform, Hyperion spatial biology platform, Maxpar reagents, and the Theia next-generation XTi platform. The purchase price consists of $5,000,000 in cash (payable via a promissory note), adjusted for closing date cash, indebtedness, working capital, and transaction expenses, plus up to $5,000,000 in additional consideration if Buyer consummates a Qualifying Exit within ten years of closing.
  https://www.sec.gov/Archives/edgar/data/1162194/0001140361-26-029964.txt

## Citations
- 0001140361-26-029964 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126029964